EVE Signs 12-Month Telehealth Deal with hubMed to Support Thousands of Patients
EVE Health Group has partnered with telehealth provider hubMed to deliver a national patient support program, enhancing care continuity for users of its women’s and men’s health products Dyspro™ and Libbo™.
- 12-month telehealth services agreement with hubMed
- Patient support program targets dysmenorrhoea and erectile dysfunction
- Registered nurses provide ongoing telehealth consultations
- Non-exclusive, usage-based fee structure with no minimum commitments
- Expansion of digital patient education platforms complements telehealth
Strategic Partnership to Enhance Patient Care
EVE Health Group (ASX, EVE) has formalised a new telehealth services agreement with Australian provider hubMed, aiming to bolster patient support for its flagship therapeutic products Dyspro™ and Libbo™. This nationwide program is designed to improve treatment adherence and patient confidence by offering accessible telehealth consultations with registered nurses.
The partnership reflects a growing recognition of the importance of continuity of care in managing chronic and often underdiagnosed conditions such as dysmenorrhoea and erectile dysfunction. By integrating regular nurse-led follow-ups, EVE hopes to address common barriers to effective treatment, including stigma, inconsistent monitoring, and delayed symptom management.
Addressing Significant Health Burdens
Dysmenorrhoea affects a majority of women of reproductive age in Australia, with substantial economic and personal impacts due to missed work and study days. Meanwhile, erectile dysfunction remains a prevalent but frequently undertreated condition among men. EVE’s Dyspro™ and Libbo™ products are positioned to meet these unmet needs through innovative delivery methods designed to improve bioavailability and patient convenience.
hubMed’s registered nurses will provide structured support, including reinforcing safe medication use, triaging concerns within their scope, and liaising with patients’ primary healthcare providers when necessary. This model aims to complement traditional medical care and enhance real-world outcomes.
Flexible, Usage-Based Agreement
The agreement is initially set for twelve months with automatic rolling renewals and is non-exclusive, allowing EVE to maintain flexibility in its telehealth partnerships. Financial terms are based on monthly patient support interactions without upfront fees or minimum volume commitments, aligning costs with actual program usage.
Alongside this telehealth initiative, EVE continues to expand its digital ecosystem, recently launching the Reclaim My Cycle platform for women and preparing new resources for men’s health ahead of Libbo™’s market introduction. These complementary efforts aim to create a consistent, evidence-based support network that strengthens patient engagement and clinical outcomes.
Looking Ahead
CEO Damian Wood emphasised the partnership’s role in addressing overlooked health conditions through reliable follow-up and trusted clinical support. As telehealth becomes an increasingly integral part of healthcare delivery, EVE’s collaboration with hubMed positions the company to better meet patient needs while potentially enhancing market penetration of its therapeutic products.
Bottom Line?
EVE’s telehealth partnership marks a pivotal step in integrating digital and clinical support, setting the stage for deeper patient engagement and potential market growth.
Questions in the middle?
- How quickly will patient uptake of the telehealth support program grow?
- What measurable impact will the program have on treatment adherence and outcomes?
- Could this model be expanded to other therapeutic areas or international markets?
